111铟标记前列腺特异性膜抗原(PSMA)放射引导手术在复发性前列腺癌挽救性淋巴结清扫中的价值:与组织病理学和临床随访的相关性
回顾性纳入2014年4月至2015年7月间31例接受111铟-PSMA放射引导手术的局部复发性前列腺癌患者,比较术中γ探针测量与切除标本组织病理结果,并评估术后PSA反应、无治疗生存及并发症。结果显示该技术有助于术中识别转移灶,但结论需进一步验证。
要点
- 111铟-PSMA放射引导手术在30/31例患者中识别出转移灶。
- 145份手术标本中51份组织学证实转移,体外放射测量48份正确分类为转移。
- 23/30例PSA下降>50%,16/30例下降>90%,18/30例降至<0.2 ng/mL。
核心结论
- 111铟-PSMA放射引导手术对计划行挽救性淋巴结清扫的前列腺癌患者术中检测小转移灶具有较高价值,可精确局部定位并切除转移组织,预期对疾病进展有有利影响;但需基于PSMA-PET影像和临床变量筛选合适患者以获得满意结果。
研究设计与样本
- 回顾性纳入2014年4月至2015年7月间31例连续接受111铟-PSMA放射引导手术的局部复发性前列腺癌患者。
- 术前中位PSA为1.3 ng/mL(四分位距0.57-2.53 ng/mL;范围0.2-13.9 ng/mL)。
- 比较切除标本体外放射活性评级(阳性 vs 阴性)与术后组织病理分析结果。
主要发现
- 30/31例患者术中识别出转移灶;共切除145份标本,51份组织学证实转移。
- 体外放射测量48份正确分类为转移,87份为无癌,4份假阴性,6份假阳性。
- 30例可随访患者中,23例PSA下降>50%,16例下降>90%,18例降至<0.2 ng/mL。
- 10/30例在术后中位125天(范围48-454天)接受进一步前列腺癌特异性治疗,其余20例在中位随访337天(范围81-591天)内未接受治疗。
- 30例中10例出现手术相关并发症(Clavien-Dindo 1级6例,3b级4例)。
关键数值与推荐
- 111铟-PSMA放射引导手术体外测量与组织病理比较:48份正确分类为转移,87份正确分类为无癌,4份假阴性,6份假阳性。
临床怎么用
- 作者认为111铟-PSMA放射引导手术对术中检测小转移灶有较高价值,可精确定位并切除转移组织,预期对疾病进展有有利影响。
- 作者指出基于PSMA-PET影像和临床变量筛选合适患者对获得满意结果至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the use of 111 In-labelled prostate-specific membrane antigen (PSMA)-I&T-based radioguided surgery (111 In-PSMA-RGS) for salvage surgery in recurrent prostate cancer (PCa) using comparison of intra-operative gamma probe measurements with histopathological results of dissected specimens. In addition, to determine the success of 111 In-PSMA-RGS with regard to postoperative prostate-specific antigen (PSA) responses, PCa-specific treatment-free survival rates and postoperative complication rates. PATIENTS AND METHODS: A total of 31 consecutive patients with localized recurrent PCa undergoing salvage surgery with PSMA-targeted radioguided surgery using a 111 In-labelled PSMA ligand between April 2014 and July 2015 were retrospectively included in this study. The preoperative (interquartile range; range) median PSA level was 1.3 (0.57-2.53 ng/mL; 0.2-13.9 ng/mL). Results of ex vivo radioactivity rating (positive vs negative) of resected tissue specimens were compared with findings of postoperative histological analysis. Best PSA response without additional treatment was determined after 111 In-PSMA-RGS, and salvage-surgery-related postoperative complications and PCa-specific additional treatments were recorded. RESULTS: In 30/31 patients, 111 In-PSMA-RGS allowed intra-operative identification of metastatic lesions. In total, 145 surgical specimens were removed and 51 showed metastatic involvement at histological analysis. According to 111 In-PSMA-RGS ex vivo measurements, 48 specimens were correctly classified as metastatic and 87 as cancer-free, four were false-negative and six were false-positive compared with histological evaluation. Follow-up information was available for 30/31 patients. PSA declines of >50% and >90% were observed in 23/30 patients and in 16/30 patients, respectively. In 18/30 patients, a PSA decline to <0.2 ng/mL was observed. In 10/30 patients further PCa-specific treatment was given after a median (range) of 125 (48-454) days post-111 In-PSMA-RGS. The remaining 20 patients remained treatment-free at a median (range) follow-up of 337 (81-591) days. Of 30 patients, 10 presented with surgery-related complications (Clavien-Dindo grade 1, n = 6, Clavien-Dindo grade 3b, n = 4). CONCLUSION: 111 In-PSMA-RGS proved to be of high value for intra-operative detection of even small metastatic lesions in patients with PCa scheduled for salvage lymphadenectomy. It allows the exact localization and resection of metastatic tissue during 111 In-PSMA-RGS and is therefore anticipated to have a beneficial influence on further disease progression; however, identification of suitable patients on the basis of PSMA-positron-emission tomography imaging as well as clinical variables is essential for satisfactory results to be obtained.
引用
- Rauscher I, Düwel C, Wirtz M, et al. Value of 111 In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. BJU Int. 2016. PMID: 27862863. doi:10.1111/bju.13713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。